Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990700 | 0.83 | BUB1 (0.36) | USP30FAAHELANEBUB1POLB | |
| SCHEMBL28507530 | 0.80 | USP30 (0.43) | USP30AAK1PRMT5WDR77FFAR1 | |
| SCHEMBL18689166 | 0.76 | UCHL1 (0.39) | USP30AAK1PRMT5WDR77FFAR1 | |
| SCHEMBL15500844 | 0.76 | KMT2A (0.40) | DGAT1UCHL1POLBNR1H2 | |
| SCHEMBL860007 | 0.75 | BUB1 (0.40) | USP30AAK1PRMT5WDR77DGAT1 | |
| SCHEMBL31258190 | 0.75 | USP30 (0.40) | USP30AAK1PRMT5WDR77FFAR1 | |
| SCHEMBL22438298 | 0.74 | USP30 (0.39) | USP30AAK1PRMT5WDR77FFAR1 | |
| SCHEMBL30293091 | 0.74 | USP30 (0.39) | USP30AAK1PRMT5WDR77FFAR1 | |
| SCHEMBL31258189 | 0.74 | UCHL1 (0.40) | USP30AAK1PRMT5WDR77FFAR1 | |
| SCHEMBL3709336 | 0.73 | USP30 (0.38) | USP30AAK1PRMT5WDR77FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100394-B1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
| WO-2025090480-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250092018-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-12152015-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11591313-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11591313-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
| EP-3105224-A1 | PYRIMIDINE IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2016-12-21 | — | — | EP | disclosed |
| US-9434714-B2 | Pyrimidine imidazole amines as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| WO-2015123174-A1 | PYRIMIDINE IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2015-08-20 | — | — | WO | disclosed |
| US-20150225371-A1 | Novel Pyrimidine Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| EP-2872507-A1 | AZAINDOLE DERIVATIVES WHICH ACT AS PI3K INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-20140343033-A1 | AZAINDOLE DERIVATIVES | Takeda Califomia, Inc. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8835420-B2 | Azaindole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20140018344-A1 | AZAINDOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
| WO-2014011568-A1 | AZAINDOLE DERIVATIVES WHICH ACT AS PI3K INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | USP30 2198/4885AAK1 2840/4885PRMT5 17/4885 |
| US-20150225371-A1 | Novel Pyrimidine Imidazole Amines as Modulators of Kinase Activity | TK1, CHEK2, DCK | USP30 2867/4885AAK1 232/4885PRMT5 351/4885 |
| US-20140343033-A1 | AZAINDOLE DERIVATIVES | PIK3R5, PIK3R1, PIK3R2 | USP30 1350/4885AAK1 1605/4885PRMT5 102/4885 |
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | STING1, IRF3, NFATC1 | USP30 2386/4885AAK1 3527/4885PRMT5 2298/4885 |
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | USP30 1651/4885AAK1 1648/4885PRMT5 2122/4885 |
| US-11591313-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | ENPP1, ENPP3, PPA1 | USP30 1651/4885AAK1 1648/4885PRMT5 2122/4885 |
| US-20250092018-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PDE7A | USP30 1672/4885AAK1 1853/4885PRMT5 2294/4885 |
| US-12152015-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | ENPP1, ENPP3, PPA1 | USP30 1651/4885AAK1 1648/4885PRMT5 2122/4885 |
| US-20140018344-A1 | AZAINDOLE DERIVATIVES | PIK3R5, PIK3R1, PIK3R2 | USP30 1350/4885AAK1 1605/4885PRMT5 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.